Identification

Name
Enalaprilat
Accession Number
DB09477
Type
Small Molecule
Groups
Approved
Description

Enalaprilat is the active metabolite of the orally available pro-drug, enalapril. Used in the treatment of hypertension, enalapril is an ACE inhibitor that prevents Angiotensin Converting Enzyme (ACE) from transforming angiotensin I into angiotensin II. As angiotensin II is responsible for vasoconstriction and sodium reabsorption in the proximal tubule of the kidney, down-regulation of this protein results in reduced blood pressure and blood fluid volume. Enalaprilat was originally created to overcome the limitations of the first ACE inhibitor, captopril, which had numerous side effects and left a metallic taste in the mouth. Removal of the problematic thiol group from captopril resulted in enalaprilat, which was then modified further with an ester to create the orally available pro-drug enalapril.

Enalaprilat is poorly orally available and is therefore only available as an intravenous injection for the treatment of hypertension when oral therapy is not possible.

Structure
Thumb
Synonyms
  • Enalaprilat anhydrous
Product Ingredients
IngredientUNIICASInChI Key
Enalaprilat dihydrateGV0O7ES0R384680-54-6MZYVOFLIPYDBGD-MLZQUWKJSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Enalaprilat Injection USPSolution1.25 mgIntravenousSterimax Inc2012-09-10Not applicableCanada
Vasotec IVSolution1.25 mgIntravenousSandoz Canada Incorporated1992-12-31Not applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
EnalaprilatInjection1.25 mg/mLIntravenousCardinal Health2000-08-232017-11-14Us
EnalaprilatInjection, solution1.25 mg/mLIntravenousTeva Parenteral Medicines, Inc.2005-10-06Not applicableUs
EnalaprilatInjection1.25 mg/mLIntravenousWest Ward Pharmaceutical2008-12-23Not applicableUs
EnalaprilatInjection, solution1.25 mg/mLIntravenousTeva Parenteral Medicines, Inc.2005-10-06Not applicableUs
EnalaprilatInjection2.5 mg/2mLIntravenousWest Ward Pharmaceutical2008-12-23Not applicableUs
EnalaprilatInjection, solution1.25 mg/mLIntravenousHospira, Inc.2000-08-22Not applicableUs
Categories
UNII
Q508Q118JM
CAS number
76420-72-9
Weight
Average: 348.3936
Monoisotopic: 348.168521888
Chemical Formula
C18H24N2O5
InChI Key
LZFZMUMEGBBDTC-QEJZJMRPSA-N
InChI
InChI=1S/C18H24N2O5/c1-12(16(21)20-11-5-8-15(20)18(24)25)19-14(17(22)23)10-9-13-6-3-2-4-7-13/h2-4,6-7,12,14-15,19H,5,8-11H2,1H3,(H,22,23)(H,24,25)/t12-,14-,15-/m0/s1
IUPAC Name
(2S)-1-[(2S)-2-{[(1S)-1-carboxy-3-phenylpropyl]amino}propanoyl]pyrrolidine-2-carboxylic acid
SMILES
[H][[email protected]@](C)(N[[email protected]@]([H])(CCC1=CC=CC=C1)C(O)=O)C(=O)N1CCC[[email protected]@]1([H])C(O)=O

Pharmacology

Indication

Enalaprilat injection is indicated for the treatment of hypertension when oral therapy is not practical.

Structured Indications
Pharmacodynamics

Enalaprilat injection results in the reduction of both supine and standing systolic and diastolic blood pressure, usually with no orthostatic component. Symptomatic postural hypotension is therefore infrequent, although it might be anticipated in volume-depleted patients. The onset of action usually occurs within fifteen minutes of administration with the maximum effect occurring within one to four hours. The abrupt withdrawal of enalaprilat has not been associated with a rapid increase in blood pressure. The duration of hemodynamic effects appears to be dose-related. However, for the recommended dose, the duration of action in most patients is approximately six hours. Following administration of enalapril, there is an increase in renal blood flow; glomerular filtration rate is usually unchanged. The effects appear to be similar in patients with renovascular hypertension.

Mechanism of action

Enalaprilat is the active metabolite of the orally available pro-drug, enalapril. Used in the treatment of hypertension, enalapril is an ACE inhibitor that prevents Angiotensin Converting Enzyme (ACE) from transforming angiotensin I into angiotensin II. As angiotensin II is responsible for vasoconstriction and sodium reabsorption in the proximal tubule of the kidney, down-regulation of this protein results in reduced blood pressure and blood fluid volume

TargetActionsOrganism
AAngiotensin-converting enzyme
inhibitor
Human
UB1 bradykinin receptorNot AvailableHuman
Absorption

Enalaprilat is poorly absorbed following oral administration, and is therefore only available as an intravenous injection.

Volume of distribution
Not Available
Protein binding

Enalaprilat is approximately 50% bound to plasma proteins. (Davies, et al. 1984)

Metabolism

Both enalapril and enalaprilat undergo renal excretion without further metabolism.

Route of elimination

Excretion of enalaprilat is primarily renal with more than 90 percent of an administered dose recovered in the urine as unchanged drug within 24 hours.

Half life

11 hr

Clearance

The disposition of enalaprilat in patients with renal insufficiency is similar to that in patients with normal renal function until the glomerular filtration rate is 30 mL/min or less. Renal clearance was 158 ± 47 ml/min.

Toxicity

Adverse experiences occurring in 0.5 to 1.0 percent of patients in controlled clinical trials included: myocardial infarction, fatigue, dizziness, fever, rash and constipation. Angioedema has also been reported in patients receiving enalaprilat, with an incidence higher in black than in non-black patients. Angioedema associated with laryngeal edema may be fatal. If angioedema of the face, extremities, lips, tongue, glottis and/or larynx occurs, treatment with enalaprilat should be discontinued and appropriate therapy instituted immediately .

Rarer adverse effects that are less likely, but should be monitored for, include development of anaphylaxis, hypotension, agranulocytosis, hepatic failure, hyperkalemia, and persistent cough.

Furthermore, ACE inhibitors should be avoided during pregnancy as they can cause fetal and neonatal morbidity and death. When pregnancy is detected, ACE inhibitors should be discontinued as soon as possible. Use during the second and third trimesters of pregnancy has been associated with fetal and neonatal injury, including hypotension, neonatal skull hypoplasia, anuria, reversible or irreversible renal failure, and death.

Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Enalaprilat.Experimental
AbacavirThe serum concentration of Abacavir can be decreased when it is combined with Enalaprilat.Approved, Investigational
AcebutololAcebutolol may increase the hypotensive activities of Enalaprilat.Approved
AceclofenacThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Aceclofenac.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Acemetacin.Approved, Experimental, Investigational
Acetylsalicylic acidAcetylsalicylic acid may decrease the antihypertensive activities of Enalaprilat.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Adapalene.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Alclofenac.Approved, Withdrawn
AldesleukinThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Aldesleukin.Approved
AlfuzosinAlfuzosin may increase the hypotensive activities of Enalaprilat.Approved, Investigational
AliskirenAliskiren may increase the hyperkalemic activities of Enalaprilat.Approved, Investigational
AllopurinolThe risk of a hypersensitivity reaction to Allopurinol is increased when it is combined with Enalaprilat.Approved
AlminoprofenThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Alminoprofen.Experimental
AlogliptinThe risk or severity of adverse effects can be increased when Alogliptin is combined with Enalaprilat.Approved
AloxiprinAloxiprin may decrease the antihypertensive activities of Enalaprilat.Experimental
AlprazolamThe serum concentration of Alprazolam can be increased when it is combined with Enalaprilat.Approved, Illicit, Investigational
AlprenololAlprenolol may increase the hypotensive activities of Enalaprilat.Approved, Withdrawn
AmbrisentanEnalaprilat may increase the hypotensive activities of Ambrisentan.Approved, Investigational
Ambroxol acefyllinateThe serum concentration of Ambroxol acefyllinate can be decreased when it is combined with Enalaprilat.Experimental, Investigational
AmifostineEnalaprilat may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideAmiloride may increase the hyperkalemic activities of Enalaprilat.Approved
AmineptineThe serum concentration of Amineptine can be increased when it is combined with Enalaprilat.Illicit, Withdrawn
AminophyllineThe serum concentration of Aminophylline can be decreased when it is combined with Enalaprilat.Approved
Aminosalicylic AcidAminosalicylic Acid may decrease the antihypertensive activities of Enalaprilat.Approved
AmiodaroneThe risk or severity of adverse effects can be increased when Amiodarone is combined with Enalaprilat.Approved, Investigational
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Enalaprilat.Approved
AmlodipineAmlodipine may increase the hypotensive activities of Enalaprilat.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Enalaprilat.Approved, Illicit
AmoxapineThe serum concentration of Amoxapine can be increased when it is combined with Enalaprilat.Approved
AmphetamineAmphetamine may increase the hypotensive activities of Enalaprilat.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Enalaprilat.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Amyl Nitrite.Approved
AndrographolideThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Andrographolide.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Anisodamine.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Antipyrine.Approved
ApocyninThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Apocynin.Investigational
ApomorphineThe risk or severity of adverse effects can be increased when Apomorphine is combined with Enalaprilat.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Apraclonidine.Approved
ApremilastThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Apremilast.Approved, Investigational
AprotininAprotinin may decrease the antihypertensive activities of Enalaprilat.Approved, Withdrawn
ArdeparinArdeparin may increase the hyperkalemic activities of Enalaprilat.Approved, Investigational, Withdrawn
AripiprazoleAripiprazole may increase the hypotensive activities of Enalaprilat.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Enalaprilat.Approved, Investigational
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Enalaprilat.Approved, Investigational
AtenololAtenolol may increase the hypotensive activities of Enalaprilat.Approved
AtorvastatinThe serum concentration of Atorvastatin can be increased when it is combined with Enalaprilat.Approved
AvanafilAvanafil may increase the antihypertensive activities of Enalaprilat.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Azapropazone.Withdrawn
AzathioprineEnalaprilat may increase the myelosuppressive activities of Azathioprine.Approved
AzelastineThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Azelastine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Enalaprilat.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Balsalazide.Approved, Investigational
BarbexacloneBarbexaclone may increase the hypotensive activities of Enalaprilat.Experimental
BarbitalBarbital may increase the hypotensive activities of Enalaprilat.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Enalaprilat.Approved
BemiparinBemiparin may increase the hyperkalemic activities of Enalaprilat.Approved, Investigational
BenazeprilBenazepril may increase the hypotensive activities of Enalaprilat.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Bendazac.Experimental
BendroflumethiazideBendroflumethiazide may increase the hypotensive activities of Enalaprilat.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Enalaprilat.Withdrawn
BenorilateThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Benorilate.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Benoxaprofen.Withdrawn
BenzydamineThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Benzydamine.Approved
BepridilBepridil may increase the hypotensive activities of Enalaprilat.Approved, Withdrawn
BetaxololBetaxolol may increase the hypotensive activities of Enalaprilat.Approved
BethanidineBethanidine may increase the hypotensive activities of Enalaprilat.Approved
BevoniumThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Bevonium.Experimental
BietaserpineBietaserpine may increase the hypotensive activities of Enalaprilat.Experimental
BimatoprostBimatoprost may increase the hypotensive activities of Enalaprilat.Approved, Investigational
BisoprololBisoprolol may increase the hypotensive activities of Enalaprilat.Approved
BoceprevirThe serum concentration of Enalaprilat can be decreased when it is combined with Boceprevir.Approved, Withdrawn
BortezomibThe risk or severity of adverse effects can be increased when Bortezomib is combined with Enalaprilat.Approved, Investigational
BosentanBosentan may increase the hypotensive activities of Enalaprilat.Approved, Investigational
BQ-123Enalaprilat may increase the hypotensive activities of BQ-123.Investigational
BretyliumBretylium may increase the hypotensive activities of Enalaprilat.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Enalaprilat.Approved
BrofaromineBrofaromine may increase the hypotensive activities of Enalaprilat.Experimental
BromfenacThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Bromfenac.Approved
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Enalaprilat.Approved, Investigational
BucillamineThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Bucillamine.Investigational
BufexamacThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Bufexamac.Experimental
BumadizoneThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Bumadizone.Experimental
BumetanideBumetanide may increase the hypotensive activities of Enalaprilat.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Enalaprilat.Approved, Investigational
BupranololBupranolol may increase the hypotensive activities of Enalaprilat.Approved
CabergolineThe serum concentration of Cabergoline can be increased when it is combined with Enalaprilat.Approved
CadralazineCadralazine may increase the hypotensive activities of Enalaprilat.Experimental
CafedrineEnalaprilat may increase the hypotensive activities of Cafedrine.Investigational
CanagliflozinCanagliflozin may increase the hyperkalemic activities of Enalaprilat.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Enalaprilat.Experimental
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Enalaprilat.Approved
CandoxatrilCandoxatril may increase the hypotensive activities of Enalaprilat.Experimental
CaptoprilCaptopril may increase the hypotensive activities of Enalaprilat.Approved
CarbamazepineThe metabolism of Enalaprilat can be increased when combined with Carbamazepine.Approved, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Enalaprilat.Approved
CaroxazoneCaroxazone may increase the hypotensive activities of Enalaprilat.Withdrawn
CarprofenThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Carprofen.Approved, Vet Approved, Withdrawn
CarteololCarteolol may increase the hypotensive activities of Enalaprilat.Approved
CarvedilolCarvedilol may increase the hypotensive activities of Enalaprilat.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Castanospermine.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Celecoxib.Approved, Investigational
CeliprololCeliprolol may increase the hypotensive activities of Enalaprilat.Approved, Investigational
CertoparinCertoparin may increase the hyperkalemic activities of Enalaprilat.Approved, Investigational
ChloroquineThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Chloroquine.Approved, Vet Approved
ChlorothiazideChlorothiazide may increase the hypotensive activities of Enalaprilat.Approved, Vet Approved
ChlorotrianiseneThe serum concentration of Chlorotrianisene can be decreased when it is combined with Enalaprilat.Investigational, Withdrawn
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Enalaprilat.Approved, Vet Approved
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Enalaprilat.Approved
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Choline magnesium trisalicylate.Approved
CicletanineEnalaprilat may increase the hypotensive activities of Cicletanine.Investigational
CilazaprilCilazapril may increase the hypotensive activities of Enalaprilat.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Enalaprilat.Approved, Investigational
CiprofloxacinEnalaprilat may increase the arrhythmogenic activities of Ciprofloxacin.Approved, Investigational
CisaprideThe serum concentration of Cisapride can be increased when it is combined with Enalaprilat.Approved, Investigational, Withdrawn
ClarithromycinThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Enalaprilat.Approved
ClevidipineThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Clevidipine.Approved
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Enalaprilat.Approved, Investigational
ClomipramineThe serum concentration of Clomipramine can be increased when it is combined with Enalaprilat.Approved, Vet Approved
ClonidineClonidine may increase the hypotensive activities of Enalaprilat.Approved
ClonixinThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Clonixin.Approved
CloranololEnalaprilat may increase the hypotensive activities of Cloranolol.Experimental
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Enalaprilat.Approved
ConivaptanThe risk or severity of adverse effects can be increased when Conivaptan is combined with Enalaprilat.Approved, Investigational
Conjugated estrogensThe serum concentration of Conjugated estrogens can be decreased when it is combined with Enalaprilat.Approved
CryptenamineCryptenamine may increase the hypotensive activities of Enalaprilat.Approved
CurcuminThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Curcumin.Investigational
CyclobenzaprineThe serum concentration of Cyclobenzaprine can be increased when it is combined with Enalaprilat.Approved
CyclopenthiazideEnalaprilat may increase the hypotensive activities of Cyclopenthiazide.Experimental
CyclophosphamideThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Enalaprilat.Approved, Investigational, Vet Approved
CyclothiazideCyclothiazide may increase the hypotensive activities of Enalaprilat.Approved
D-LimoneneThe risk or severity of adverse effects can be increased when Enalaprilat is combined with D-Limonene.Investigational
DalteparinDalteparin may increase the hyperkalemic activities of Enalaprilat.Approved
DapagliflozinThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Dapagliflozin.Approved
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Enalaprilat.Investigational
DebrisoquinDebrisoquin may increase the hypotensive activities of Enalaprilat.Approved, Investigational
DelaprilEnalaprilat may increase the hypotensive activities of Delapril.Experimental
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Enalaprilat.Approved
dersalazinedersalazine may decrease the antihypertensive activities of Enalaprilat.Investigational
DeserpidineEnalaprilat may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Enalaprilat.Approved
DesipramineThe serum concentration of Desipramine can be increased when it is combined with Enalaprilat.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Dexmedetomidine.Approved, Vet Approved
DiazoxideDiazoxide may increase the hypotensive activities of Enalaprilat.Approved
DibenzepinThe serum concentration of Dibenzepin can be increased when it is combined with Enalaprilat.Experimental
DiclofenacThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Diclofenac.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Diclofenamide.Approved
DienestrolThe serum concentration of Dienestrol can be decreased when it is combined with Enalaprilat.Approved, Investigational
diethylnorsperminediethylnorspermine may increase the hypotensive activities of Enalaprilat.Investigational
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Enalaprilat.Approved, Investigational
DifenpiramideThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Difenpiramide.Experimental
DiflunisalDiflunisal may decrease the antihypertensive activities of Enalaprilat.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Enalaprilat.Approved
DihydralazineDihydralazine may increase the hypotensive activities of Enalaprilat.Investigational
DihydroergotamineThe serum concentration of Dihydroergotamine can be increased when it is combined with Enalaprilat.Approved
DiltiazemThe metabolism of Diltiazem can be decreased when combined with Enalaprilat.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Dinutuximab.Approved
DipyridamoleThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Dipyridamole.Approved
DorzolamideDorzolamide may increase the hypotensive activities of Enalaprilat.Approved
DosulepinThe serum concentration of Dosulepin can be increased when it is combined with Enalaprilat.Approved
DoxazosinDoxazosin may increase the hypotensive activities of Enalaprilat.Approved
DoxepinThe serum concentration of Doxepin can be increased when it is combined with Enalaprilat.Approved
DrospirenoneEnalaprilat may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Droxicam.Approved
DuloxetineEnalaprilat may increase the orthostatic hypotensive activities of Duloxetine.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Duvelisib.Investigational
DyphyllineThe serum concentration of Dyphylline can be decreased when it is combined with Enalaprilat.Approved
E-6201The risk or severity of adverse effects can be increased when Enalaprilat is combined with E-6201.Investigational
EfonidipineEfonidipine may increase the hypotensive activities of Enalaprilat.Approved, Investigational
EmpagliflozinThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Empagliflozin.Approved
EnalaprilEnalapril may increase the hypotensive activities of Enalaprilat.Approved, Vet Approved
EndralazineEndralazine may increase the hypotensive activities of Enalaprilat.Experimental
EnfuvirtideThe serum concentration of Enfuvirtide can be increased when it is combined with Enalaprilat.Approved, Investigational
EnoxaparinEnoxaparin may increase the hyperkalemic activities of Enalaprilat.Approved
EpanololEnalaprilat may increase the hypotensive activities of Epanolol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Epirizole.Approved
EplerenoneEplerenone may increase the hyperkalemic activities of Enalaprilat.Approved
EpoprostenolEpoprostenol may increase the hypotensive activities of Enalaprilat.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Enalaprilat.Approved
Ergoloid mesylateThe serum concentration of Ergoloid mesylate can be increased when it is combined with Enalaprilat.Approved
ErgonovineThe serum concentration of Ergonovine can be increased when it is combined with Enalaprilat.Approved
ErgotamineThe serum concentration of Ergotamine can be increased when it is combined with Enalaprilat.Approved
EsmirtazapineThe serum concentration of Esmirtazapine can be increased when it is combined with Enalaprilat.Investigational
EsmololThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Esmolol.Approved
EstradiolThe serum concentration of Estradiol can be decreased when it is combined with Enalaprilat.Approved, Investigational, Vet Approved
EstramustineThe serum concentration of Estramustine can be decreased when it is combined with Enalaprilat.Approved
Estrogens, esterifiedThe serum concentration of Estrogens, esterified can be decreased when it is combined with Enalaprilat.Approved
Estrone sulfateThe serum concentration of Estrone sulfate can be decreased when it is combined with Enalaprilat.Approved
Etacrynic acidEtacrynic acid may increase the hypotensive activities of Enalaprilat.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Etanercept.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Ethenzamide.Experimental
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Enalaprilat.Approved
EtodolacThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Etofenamate.Approved, Investigational
EtoricoxibThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Etoricoxib.Approved, Investigational
EtravirineThe serum concentration of Etravirine can be decreased when it is combined with Enalaprilat.Approved
Evening primrose oilThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Evening primrose oil.Approved, Investigational
EverolimusThe risk or severity of adverse effects can be increased when Everolimus is combined with Enalaprilat.Approved
exisulindThe risk or severity of adverse effects can be increased when Enalaprilat is combined with exisulind.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Felbinac.Experimental
FelodipineFelodipine may increase the hypotensive activities of Enalaprilat.Approved, Investigational
FenbufenThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Fenbufen.Approved
FenoldopamFenoldopam may increase the hypotensive activities of Enalaprilat.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Fenoprofen.Approved
FentiazacThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Fentiazac.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Feprazone.Experimental
Ferulic acidFerulic acid may increase the hypotensive activities of Enalaprilat.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Enalaprilat.Approved, Investigational
FloctafenineThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Floctafenine.Approved, Withdrawn
FlunixinThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Flunixin.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Flunoxaprofen.Experimental
FlurbiprofenThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Flurbiprofen.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Enalaprilat.Experimental
FosinoprilFosinopril may increase the hypotensive activities of Enalaprilat.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Enalaprilat.Approved, Investigational, Vet Approved
FurosemideFurosemide may increase the hypotensive activities of Enalaprilat.Approved, Vet Approved
GarlicThe serum concentration of Enalaprilat can be decreased when it is combined with Garlic.Approved
GuacetisalGuacetisal may decrease the antihypertensive activities of Enalaprilat.Experimental
GuanabenzGuanabenz may increase the hypotensive activities of Enalaprilat.Approved, Investigational
GuanadrelGuanadrel may increase the hypotensive activities of Enalaprilat.Approved
GuanazodineEnalaprilat may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineGuanethidine may increase the hypotensive activities of Enalaprilat.Approved
GuanfacineGuanfacine may increase the hypotensive activities of Enalaprilat.Approved, Investigational
GuanoclorEnalaprilat may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzEnalaprilat may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanEnalaprilat may increase the hypotensive activities of Guanoxan.Experimental
HalothaneThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Halothane.Approved, Vet Approved
HarmalineHarmaline may increase the hypotensive activities of Enalaprilat.Experimental
Hemoglobin crosfumarilHemoglobin crosfumaril may decrease the antihypertensive activities of Enalaprilat.Experimental
HeparinHeparin may increase the hyperkalemic activities of Enalaprilat.Approved, Investigational
HexamethoniumHexamethonium may increase the hypotensive activities of Enalaprilat.Experimental
HexestrolThe serum concentration of Hexestrol can be decreased when it is combined with Enalaprilat.Withdrawn
HexobarbitalHexobarbital may increase the hypotensive activities of Enalaprilat.Approved
HigenamineThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Higenamine.Investigational
HydracarbazineHydracarbazine may increase the hypotensive activities of Enalaprilat.Experimental
HydralazineHydralazine may increase the hypotensive activities of Enalaprilat.Approved
HydrochlorothiazideHydrochlorothiazide may increase the hypotensive activities of Enalaprilat.Approved, Vet Approved
HydroflumethiazideHydroflumethiazide may increase the hypotensive activities of Enalaprilat.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Ibuprofen.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Ibuproxam.Withdrawn
IcatibantIcatibant may decrease the antihypertensive activities of Enalaprilat.Approved
IloprostIloprost may increase the hypotensive activities of Enalaprilat.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Imidapril.Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Imidazole salicylate.Experimental
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Enalaprilat.Approved
IndapamideIndapamide may increase the hypotensive activities of Enalaprilat.Approved
IndenololIndenolol may increase the hypotensive activities of Enalaprilat.Withdrawn
IndobufenThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Indobufen.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Indomethacin.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Indoprofen.Withdrawn
IndoraminIndoramin may increase the hypotensive activities of Enalaprilat.Withdrawn
IprindoleThe serum concentration of Iprindole can be increased when it is combined with Enalaprilat.Experimental
IproclozideIproclozide may increase the hypotensive activities of Enalaprilat.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Enalaprilat.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Enalaprilat.Approved, Investigational
IronThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Iron.Approved
Iron DextranThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Iron Dextran.Approved, Vet Approved
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Enalaprilat.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Isoflurane.Approved, Vet Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Isosorbide Dinitrate.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Isosorbide Mononitrate.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Isoxicam.Withdrawn
IsoxsuprineThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Isoxsuprine.Approved, Withdrawn
IsradipineIsradipine may increase the hypotensive activities of Enalaprilat.Approved
KebuzoneThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Kebuzone.Experimental
KetanserinKetanserin may increase the hypotensive activities of Enalaprilat.Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Ketoprofen.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Ketorolac.Approved
LabetalolLabetalol may increase the hypotensive activities of Enalaprilat.Approved
LacidipineLacidipine may increase the hypotensive activities of Enalaprilat.Approved, Investigational
Lanthanum carbonateThe serum concentration of Enalaprilat can be decreased when it is combined with Lanthanum carbonate.Approved
LatanoprostLatanoprost may increase the hypotensive activities of Enalaprilat.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Leflunomide.Approved, Investigational
LercanidipineLercanidipine may increase the hypotensive activities of Enalaprilat.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Levobupivacaine.Approved, Investigational
LevodopaEnalaprilat may increase the orthostatic hypotensive activities of Levodopa.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Levosimendan.Approved, Investigational
LinagliptinThe risk or severity of adverse effects can be increased when Linagliptin is combined with Enalaprilat.Approved
LinsidomineEnalaprilat may increase the hypotensive activities of Linsidomine.Experimental
LisinoprilLisinopril may increase the hypotensive activities of Enalaprilat.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Lisofylline.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Enalaprilat.Approved
LofepramineThe serum concentration of Lofepramine can be increased when it is combined with Enalaprilat.Experimental
LofexidineLofexidine may increase the hypotensive activities of Enalaprilat.Approved, Investigational
LonazolacThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Lonazolac.Experimental
LornoxicamThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Lornoxicam.Approved, Investigational
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Enalaprilat.Approved
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Enalaprilat.Approved, Investigational
LoxoprofenThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Loxoprofen.Approved, Investigational
LumiracoxibThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Lumiracoxib.Approved, Investigational
MacitentanEnalaprilat may increase the hypotensive activities of Macitentan.Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Magnesium salicylate.Approved
ManidipineManidipine may increase the hypotensive activities of Enalaprilat.Approved, Investigational
MannitolThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Mannitol.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Masoprocol.Approved, Investigational
MebanazineMebanazine may increase the hypotensive activities of Enalaprilat.Withdrawn
MecamylamineMecamylamine may increase the hypotensive activities of Enalaprilat.Approved
Meclofenamic acidThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Meclofenamic acid.Approved, Vet Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Mefenamic acid.Approved
MeloxicamThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Meloxicam.Approved, Vet Approved
MesalazineMesalazine may decrease the antihypertensive activities of Enalaprilat.Approved
MestranolThe serum concentration of Mestranol can be decreased when it is combined with Enalaprilat.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Metamizole.Investigational, Withdrawn
MethallenestrilThe serum concentration of Methallenestril can be decreased when it is combined with Enalaprilat.Experimental
MethazolamideThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Methazolamide.Approved
MethohexitalMethohexital may increase the hypotensive activities of Enalaprilat.Approved
MethoserpidineEnalaprilat may increase the hypotensive activities of Methoserpidine.Experimental
MethyclothiazideMethyclothiazide may increase the hypotensive activities of Enalaprilat.Approved
Methyl salicylateMethyl salicylate may decrease the antihypertensive activities of Enalaprilat.Approved, Vet Approved
MethyldopaMethyldopa may increase the hypotensive activities of Enalaprilat.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Enalaprilat.Approved, Investigational
MethylergometrineThe serum concentration of Methylergometrine can be increased when it is combined with Enalaprilat.Approved
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Enalaprilat.Approved, Investigational
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Enalaprilat.Approved
MetipranololMetipranolol may increase the hypotensive activities of Enalaprilat.Approved
MetolazoneMetolazone may increase the hypotensive activities of Enalaprilat.Approved
MetoprololMetoprolol may increase the hypotensive activities of Enalaprilat.Approved, Investigational
MetyrosineEnalaprilat may increase the hypotensive activities of Metyrosine.Approved
MibefradilMibefradil may increase the hypotensive activities of Enalaprilat.Investigational, Withdrawn
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Enalaprilat.Approved, Illicit
MinaprineMinaprine may increase the hypotensive activities of Enalaprilat.Approved
MinoxidilMinoxidil may increase the hypotensive activities of Enalaprilat.Approved
MirodenafilMirodenafil may increase the antihypertensive activities of Enalaprilat.Investigational
MirtazapineThe serum concentration of Mirtazapine can be increased when it is combined with Enalaprilat.Approved
MizoribineThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Mizoribine.Investigational
MoclobemideMoclobemide may increase the hypotensive activities of Enalaprilat.Approved
MoexiprilMoexipril may increase the hypotensive activities of Enalaprilat.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Mofebutazone.Experimental
MolsidomineMolsidomine may increase the hypotensive activities of Enalaprilat.Approved, Investigational
MorphineThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Morphine.Approved, Investigational
MoxonidineMoxonidine may increase the hypotensive activities of Enalaprilat.Approved, Investigational
MuzolimineEnalaprilat may increase the hypotensive activities of Muzolimine.Experimental
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Mycophenolate mofetil.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Mycophenolic acid.Approved
NabiloneThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Nabilone.Approved, Investigational
NabumetoneThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Nabumetone.Approved
NadololNadolol may increase the hypotensive activities of Enalaprilat.Approved
NadroparinNadroparin may increase the hyperkalemic activities of Enalaprilat.Approved
NafamostatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Nafamostat.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Naftifine.Approved
NaftopidilEnalaprilat may increase the hypotensive activities of Naftopidil.Investigational
NaproxenThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Naproxen.Approved, Vet Approved
NebivololNebivolol may increase the hypotensive activities of Enalaprilat.Approved, Investigational
NefazodoneThe serum concentration of Nefazodone can be increased when it is combined with Enalaprilat.Approved, Withdrawn
NepafenacThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Nepafenac.Approved
NesiritideThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Nesiritide.Approved, Investigational
NialamideNialamide may increase the hypotensive activities of Enalaprilat.Withdrawn
NicardipineNicardipine may increase the hypotensive activities of Enalaprilat.Approved
NicorandilNicorandil may increase the hyperkalemic activities of Enalaprilat.Approved, Investigational
NifedipineThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Nifedipine.Approved
NifenazoneThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Nifenazone.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Niflumic Acid.Approved
NiguldipineNiguldipine may increase the hypotensive activities of Enalaprilat.Experimental
NilvadipineNilvadipine may increase the hypotensive activities of Enalaprilat.Approved, Investigational
NimesulideThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Nimesulide.Approved, Investigational, Withdrawn
NimodipineNimodipine may increase the hypotensive activities of Enalaprilat.Approved
NisoldipineNisoldipine may increase the hypotensive activities of Enalaprilat.Approved
NitrendipineNitrendipine may increase the hypotensive activities of Enalaprilat.Approved, Investigational
Nitric OxideThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Nitric Oxide.Approved
NitroaspirinNitroaspirin may decrease the antihypertensive activities of Enalaprilat.Investigational
NitroglycerinThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Nitroglycerin.Approved, Investigational
NitroprussideNitroprusside may increase the hypotensive activities of Enalaprilat.Approved
NortriptylineThe serum concentration of Nortriptyline can be increased when it is combined with Enalaprilat.Approved
ObinutuzumabEnalaprilat may increase the hypotensive activities of Obinutuzumab.Approved
OctamoxinOctamoxin may increase the hypotensive activities of Enalaprilat.Withdrawn
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Enalaprilat.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Olopatadine.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Olsalazine.Approved
OmapatrilatOmapatrilat may increase the hypotensive activities of Enalaprilat.Investigational
OpipramolThe serum concentration of Opipramol can be increased when it is combined with Enalaprilat.Investigational
OrgoteinThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Orgotein.Vet Approved
OxaprozinThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Oxaprozin.Approved
OxprenololOxprenolol may increase the hypotensive activities of Enalaprilat.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Oxyphenbutazone.Approved, Withdrawn
PaclitaxelThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Paclitaxel.Approved, Vet Approved
PapaverineThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Papaverine.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Parecoxib.Approved
PargylinePargyline may increase the hypotensive activities of Enalaprilat.Approved
ParnaparinParnaparin may increase the hyperkalemic activities of Enalaprilat.Approved, Investigational
ParthenolideThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Parthenolide.Investigational
PenbutololPenbutolol may increase the hypotensive activities of Enalaprilat.Approved, Investigational
PentobarbitalPentobarbital may increase the hypotensive activities of Enalaprilat.Approved, Vet Approved
PentoliniumPentolinium may increase the hypotensive activities of Enalaprilat.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Enalaprilat.Approved, Investigational
PerindoprilPerindopril may increase the hypotensive activities of Enalaprilat.Approved
PethidineThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Pethidine.Approved
PhenelzinePhenelzine may increase the hypotensive activities of Enalaprilat.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Enalaprilat.Withdrawn
PhenobarbitalPhenobarbital may increase the hypotensive activities of Enalaprilat.Approved
PhenoxybenzaminePhenoxybenzamine may increase the hypotensive activities of Enalaprilat.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Enalaprilat.Withdrawn
PhentolaminePhentolamine may increase the hypotensive activities of Enalaprilat.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Phenylbutazone.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Pimecrolimus.Approved, Investigational
PimozideThe serum concentration of Pimozide can be increased when it is combined with Enalaprilat.Approved
PinacidilPinacidil may increase the hypotensive activities of Enalaprilat.Withdrawn
PindololPindolol may increase the hypotensive activities of Enalaprilat.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Pipamperone.Approved, Investigational
PiretanidePiretanide may increase the hypotensive activities of Enalaprilat.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Pirfenidone.Approved, Investigational
PirlindolePirlindole may increase the hypotensive activities of Enalaprilat.Approved
PiroxicamThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Piroxicam.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Pirprofen.Experimental
PivhydrazinePivhydrazine may increase the hypotensive activities of Enalaprilat.Withdrawn
Platelet Activating FactorPlatelet Activating Factor may increase the hypotensive activities of Enalaprilat.Experimental
PolythiazidePolythiazide may increase the hypotensive activities of Enalaprilat.Approved
PramipexoleThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Pramipexole.Approved, Investigational
PranoprofenThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Pranoprofen.Experimental, Investigational
PrazosinPrazosin may increase the hypotensive activities of Enalaprilat.Approved
PregabalinThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Pregabalin.Approved, Illicit, Investigational
PrimidonePrimidone may increase the hypotensive activities of Enalaprilat.Approved, Vet Approved
ProcarbazineProcarbazine may increase the hypotensive activities of Enalaprilat.Approved
ProglumetacinThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Proglumetacin.Experimental
PropacetamolThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Propacetamol.Approved, Investigational
PropofolThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Propofol.Approved, Investigational, Vet Approved
PropranololPropranolol may increase the hypotensive activities of Enalaprilat.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Propyphenazone.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Proquazone.Experimental
ProtriptylineThe serum concentration of Protriptyline can be increased when it is combined with Enalaprilat.Approved
PTC299The risk or severity of adverse effects can be increased when Enalaprilat is combined with PTC299.Investigational
QuetiapineThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Quetiapine.Approved
QuinaprilQuinapril may increase the hypotensive activities of Enalaprilat.Approved, Investigational
QuinethazoneQuinethazone may increase the hypotensive activities of Enalaprilat.Approved
QuinineQuinine may increase the hypotensive activities of Enalaprilat.Approved
RamiprilRamipril may increase the hypotensive activities of Enalaprilat.Approved
RasagilineRasagiline may increase the hypotensive activities of Enalaprilat.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Remifentanil.Approved
RemikirenRemikiren may increase the hypotensive activities of Enalaprilat.Approved
RescinnamineEnalaprilat may increase the hypotensive activities of Rescinnamine.Approved
ReserpineReserpine may increase the hypotensive activities of Enalaprilat.Approved, Investigational
ResveratrolThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Resveratrol.Approved, Experimental, Investigational
ReviparinReviparin may increase the hyperkalemic activities of Enalaprilat.Approved, Investigational
RilmenidineRilmenidine may increase the hypotensive activities of Enalaprilat.Investigational
RiociguatThe serum concentration of Riociguat can be increased when it is combined with Enalaprilat.Approved
RisperidoneEnalaprilat may increase the hypotensive activities of Risperidone.Approved, Investigational
RituximabEnalaprilat may increase the hypotensive activities of Rituximab.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Rofecoxib.Investigational, Withdrawn
RopiniroleThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Ropivacaine.Approved
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Enalaprilat.Approved
RotigotineThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Rotigotine.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Sacubitril.Approved
SafrazineSafrazine may increase the hypotensive activities of Enalaprilat.Withdrawn
SalicylamideThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Salicylamide.Approved
Salicylic acidSalicylic acid may decrease the antihypertensive activities of Enalaprilat.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Salsalate.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Enalaprilat.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Enalaprilat.Investigational
SaxagliptinThe risk or severity of adverse effects can be increased when Saxagliptin is combined with Enalaprilat.Approved
SecobarbitalSecobarbital may increase the hypotensive activities of Enalaprilat.Approved, Vet Approved
SelegilineSelegiline may increase the hypotensive activities of Enalaprilat.Approved, Investigational, Vet Approved
SelexipagEnalaprilat may increase the hypotensive activities of Selexipag.Approved
SemapimodThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Semapimod.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Seratrodast.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Serrapeptase.Investigational
SevofluraneThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Sevoflurane.Approved, Vet Approved
SildenafilThe serum concentration of Sildenafil can be increased when it is combined with Enalaprilat.Approved, Investigational
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Enalaprilat.Approved
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Enalaprilat.Approved
SirolimusThe risk or severity of adverse effects can be increased when Sirolimus is combined with Enalaprilat.Approved, Investigational
SitagliptinThe risk or severity of adverse effects can be increased when Sitagliptin is combined with Enalaprilat.Approved, Investigational
SitaxentanEnalaprilat may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium aurothiomalateThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Sodium aurothiomalate.Approved
Sodium NitriteThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Sodium Nitrite.Approved
Sodium phosphateEnalaprilat may increase the nephrotoxic activities of Sodium phosphate.Approved
SotalolThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Sotalol.Approved
SpiraprilSpirapril may increase the hypotensive activities of Enalaprilat.Approved
SpironolactoneSpironolactone may increase the hyperkalemic activities of Enalaprilat.Approved
SRT501The risk or severity of adverse effects can be increased when Enalaprilat is combined with SRT501.Investigational
St. John's WortThe metabolism of Enalaprilat can be increased when combined with St. John's Wort.Investigational, Nutraceutical
StreptokinaseThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Streptokinase.Approved, Investigational
SufentanilThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Sufentanil.Approved, Investigational
SulfasalazineThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Sulfasalazine.Approved
SulindacThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Sulindac.Approved
SuprofenThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Suprofen.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Suxibuzone.Experimental
Synthetic Conjugated Estrogens, AThe serum concentration of Synthetic Conjugated Estrogens, A can be decreased when it is combined with Enalaprilat.Approved
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Enalaprilat.Approved, Investigational
TadalafilTadalafil may increase the antihypertensive activities of Enalaprilat.Approved, Investigational
TalinololEnalaprilat may increase the hypotensive activities of Talinolol.Investigational
TamsulosinThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Tamsulosin.Approved, Investigational
TarenflurbilThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Tarenflurbil.Investigational
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Enalaprilat.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Enalaprilat.Approved, Investigational
TemocaprilTemocapril may increase the hypotensive activities of Enalaprilat.Experimental, Investigational
TemsirolimusThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Temsirolimus.Approved
TenidapThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Tenidap.Experimental
TenoxicamThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Tenoxicam.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Tepoxalin.Vet Approved
TerazosinThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Terazosin.Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Teriflunomide.Approved
TerlipressinTerlipressin may increase the hypotensive activities of Enalaprilat.Approved, Investigational
TetrahydropalmatineEnalaprilat may increase the hypotensive activities of Tetrahydropalmatine.Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Thalidomide.Approved, Investigational, Withdrawn
TheodrenalineEnalaprilat may increase the hypotensive activities of Theodrenaline.Investigational
TheophyllineThe serum concentration of Theophylline can be decreased when it is combined with Enalaprilat.Approved
ThiamylalThiamylal may increase the hypotensive activities of Enalaprilat.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Enalaprilat.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Thioridazine.Approved, Withdrawn
TianeptineThe serum concentration of Tianeptine can be increased when it is combined with Enalaprilat.Approved, Investigational
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Tiaprofenic acid.Approved
TiboloneTibolone may increase the hypotensive activities of Enalaprilat.Approved, Investigational
TicrynafenTicrynafen may increase the hypotensive activities of Enalaprilat.Withdrawn
TimololTimolol may increase the hypotensive activities of Enalaprilat.Approved
TinoridineThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Tinoridine.Investigational
TinzaparinTinzaparin may increase the hyperkalemic activities of Enalaprilat.Approved
TipranavirThe serum concentration of Enalaprilat can be decreased when it is combined with Tipranavir.Approved, Investigational
TizanidineTizanidine may increase the hypotensive activities of Enalaprilat.Approved
TolazolineTolazoline may increase the hypotensive activities of Enalaprilat.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Tolcapone.Approved, Withdrawn
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Tolfenamic Acid.Approved
TolmetinThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Tolmetin.Approved
TolonidineEnalaprilat may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the hypotensive activities of Enalaprilat.Approved
TolvaptanTolvaptan may increase the hyperkalemic activities of Enalaprilat.Approved
TorasemideTorasemide may increase the hypotensive activities of Enalaprilat.Approved
TrandolaprilTrandolapril may increase the hypotensive activities of Enalaprilat.Approved
TranilastThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Tranilast.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Enalaprilat.Experimental
TranylcypromineTranylcypromine may increase the hypotensive activities of Enalaprilat.Approved
TravoprostTravoprost may increase the hypotensive activities of Enalaprilat.Approved
TreprostinilTreprostinil may increase the hypotensive activities of Enalaprilat.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneTriamterene may increase the hyperkalemic activities of Enalaprilat.Approved
TriazolamThe serum concentration of Triazolam can be increased when it is combined with Enalaprilat.Approved
TribenosideThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Tribenoside.Experimental
TrichlormethiazideTrichlormethiazide may increase the hypotensive activities of Enalaprilat.Approved, Vet Approved
TrimazosinTrimazosin may increase the hypotensive activities of Enalaprilat.Experimental
TrimethaphanTrimethaphan may increase the hypotensive activities of Enalaprilat.Approved, Investigational
TrimethoprimTrimethoprim may increase the hyperkalemic activities of Enalaprilat.Approved, Vet Approved
TrimipramineThe serum concentration of Trimipramine can be increased when it is combined with Enalaprilat.Approved
TriptolideThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Triptolide.Investigational
Trolamine salicylateTrolamine salicylate may decrease the antihypertensive activities of Enalaprilat.Approved
UdenafilUdenafil may increase the antihypertensive activities of Enalaprilat.Approved, Investigational
UnoprostoneUnoprostone may increase the hypotensive activities of Enalaprilat.Approved
UrapidilUrapidil may increase the hypotensive activities of Enalaprilat.Investigational
ValdecoxibThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Valdecoxib.Investigational, Withdrawn
Valproic AcidThe serum concentration of Valproic Acid can be decreased when it is combined with Enalaprilat.Approved, Investigational
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Enalaprilat.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Enalaprilat.Approved
VerapamilThe metabolism of Verapamil can be decreased when combined with Enalaprilat.Approved
VildagliptinThe risk or severity of adverse effects can be increased when Vildagliptin is combined with Enalaprilat.Approved, Investigational
VincamineEnalaprilat may increase the hypotensive activities of Vincamine.Experimental
VinpocetineEnalaprilat may increase the hypotensive activities of Vinpocetine.Investigational
XipamideEnalaprilat may increase the hypotensive activities of Xipamide.Experimental
XylometazolineXylometazoline may increase the hypotensive activities of Enalaprilat.Approved
YohimbineYohimbine may decrease the antihypertensive activities of Enalaprilat.Approved, Vet Approved
ZaltoprofenThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Zaltoprofen.Approved, Investigational
ZidovudineThe serum concentration of Zidovudine can be decreased when it is combined with Enalaprilat.Approved
ZileutonThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Zileuton.Approved, Investigational, Withdrawn
ZofenoprilEnalaprilat may increase the hypotensive activities of Zofenopril.Experimental
ZomepiracThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Zomepirac.Withdrawn
Food Interactions
Not Available

References

General References
  1. Ulm EH: Enalapril maleate (MK-421), a potent, nonsulfhydryl angiotensin-converting enzyme inhibitor: absorption, disposition, and metabolism in man. Drug Metab Rev. 1983;14(1):99-110. [PubMed:6301792]
  2. Davies RO, Gomez HJ, Irvin JD, Walker JF: An overview of the clinical pharmacology of enalapril. Br J Clin Pharmacol. 1984;18 Suppl 2:215S-229S. [PubMed:6099737]
External Links
Human Metabolome Database
HMDB41886
KEGG Drug
D03769
KEGG Compound
C11720
PubChem Compound
5462501
PubChem Substance
347827859
ChemSpider
4575429
BindingDB
50367254
ChEBI
4786
ChEMBL
CHEMBL577
HET
EAL
RxList
RxList Drug Page
Wikipedia
Enalaprilat
AHFS Codes
  • 24:32.04 — Angiotensin-converting Enzyme Inhibitors
PDB Entries
1uze / 2x90
FDA label
Download (2.99 MB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3CompletedTreatmentCongestive Cardiomyopathy / High Blood Pressure (Hypertension)1
4CompletedBasic ScienceType 2 Diabetes Mellitus1
Not AvailableCompletedNot AvailableSalt-sensitive Hypertension1
Not AvailableCompletedHealth Services ResearchIdiopathic orthostatic hypotension / Spinal Cord Injuries (SCI)1
Not AvailableCompletedTreatmentCVA (Cerebrovascular Accident) / Intracerebral Hemorrhage / Intracranial Hemorrhages1
Not AvailableCompletedTreatmentHigh Blood Pressure (Hypertension) / Type 2 Diabetes Mellitus1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
InjectionIntravenous1.25 mg/mL
InjectionIntravenous2.5 mg/2mL
Injection, solutionIntravenous1.25 mg/mL
SolutionIntravenous1.25 mg
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.876 mg/mLALOGPS
logP-0.09ALOGPS
logP-1.1ChemAxon
logS-2.6ALOGPS
pKa (Strongest Acidic)3.13ChemAxon
pKa (Strongest Basic)7.83ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area106.94 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity90.06 m3·mol-1ChemAxon
Polarizability35.82 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as dipeptides. These are organic compounds containing a sequence of exactly two alpha-amino acids joined by a peptide bond.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboxylic acids and derivatives
Sub Class
Amino acids, peptides, and analogues
Direct Parent
Dipeptides
Alternative Parents
Proline and derivatives / N-acyl-L-alpha-amino acids / Alpha amino acid amides / L-alpha-amino acids / Pyrrolidine carboxylic acids / N-acylpyrrolidines / Aralkylamines / Dicarboxylic acids and derivatives / Benzene and substituted derivatives / Tertiary carboxylic acid amides
show 8 more
Substituents
Alpha-dipeptide / N-acyl-alpha-amino acid / Proline or derivatives / N-acyl-alpha amino acid or derivatives / N-acyl-l-alpha-amino acid / Alpha-amino acid amide / Alpha-amino acid / Alpha-amino acid or derivatives / L-alpha-amino acid / N-acylpyrrolidine
show 26 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
dipeptide, dicarboxylic acid (CHEBI:4786)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Zinc ion binding
Specific Function
Converts angiotensin I to angiotensin II by release of the terminal His-Leu, this results in an increase of the vasoconstrictor activity of angiotensin. Also able to inactivate bradykinin, a potent...
Gene Name
ACE
Uniprot ID
P12821
Uniprot Name
Angiotensin-converting enzyme
Molecular Weight
149713.675 Da
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Peptide binding
Specific Function
This is a receptor for bradykinin. Could be a factor in chronic pain and inflammation.
Gene Name
BDKRB1
Uniprot ID
P46663
Uniprot Name
B1 bradykinin receptor
Molecular Weight
40494.29 Da
References
  1. Ignjatovic T, Tan F, Brovkovych V, Skidgel RA, Erdos EG: Novel mode of action of angiotensin I converting enzyme inhibitors: direct activation of bradykinin B1 receptor. J Biol Chem. 2002 May 10;277(19):16847-52. Epub 2002 Mar 5. [PubMed:11880373]

Drug created on November 30, 2015 12:10 / Updated on December 10, 2017 17:18